VivoSeq
Other

CLE

0

Pipeline Programs↗

22

Active Trials↗

15

Companies Involved↗

CLE is an early-stage landscape with 0 programs across 15 companies. The most active players are Bayer, Aciex Therapeutics, Inc., Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

30/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalA

Aciex Therapeutics, Inc.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalD

Diasome Pharmaceuticals

0 programs

PreclinicalChangchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

0 programs

PreclinicalC

CuraSen Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

143

clinical trials

Completed76 · 53%
Unknown status28 · 20%
Withdrawn11 · 8%
Recruiting11 · 8%
Not yet recruiting6 · 4%
Terminated6 · 4%
Other5 · 3%

Clinical Trials

Trial Activity

143 trials

Nucleoside Therapy in Patients With Telomere Biology Disorders
Recruiting·—·Phase 1·NCT06817590·36 enrolled
Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.
Recruiting·UUniversity of Copenhagen·N/A·NCT06654986·36 enrolled
Study of Foam Sclerotherapy Versus Ambulatory Phlebectomy
Recruiting·IImperial College London·Phase 4·NCT03416413·160 enrolled
Pharmacokinetic Study of Oligonucleotides in Maixuekang Capsules
Recruiting·NNanfang Hospital, Southern Medical University·Phase 1·NCT06823895·12 enrolled
Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION)
Recruiting·UUniversity Hospital, Clermont-Ferrand·Phase 3·NCT07374042·100 enrolled
Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard Toothbrush
Recruiting·—·Phase 3·NCT07471477·60 enrolled
IUI With Letrozole Versus in Natural Cycle
Recruiting·PPeking University Third Hospital·N/A·NCT04169451·982 enrolled
Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy
Recruiting·MMichael D. Straiko, MD·Phase 2·NCT03813056·72 enrolled
Rickettsia Clearance Study
Recruiting·—·Phase 2/3·NCT05972772·72 enrolled
A Study to See if a Combination of Vitamins That is Injected Into a Muscle is as Good and Safe as a Vitamin That is Taken by Mouth
Recruiting·MMedice Arzneimittel Pütter GmbH & Co KG·Phase 4·NCT07029698·46 enrolled
Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance
Recruiting·FFirst Affiliated Hospital of Fujian Medical University·N/A·NCT07257562·40 enrolled
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Phase 2/3·NCT07145333·600 enrolled
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Phase 2/3·NCT01064466·600 enrolled
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Phase 2/3·NCT03348670·600 enrolled
Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Phase 2/3·NCT06062810·600 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)